NCT04852887ClinicalTrials.gov

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.

Diese Studie kontaktieren

Kurz gefasst

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Phase 31.670 Teilnehmende gesucht832 Studienzentren4 Länder

Kategorien

Onkologie60%Endokrin und metabolisch27%Dermatologie13%

In 1 Register registriert

ClinicalTrials.govNCT04852887Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Monaten

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2021-04-21; recorded start 2021-06-23
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Not stated: Open label (no blinding)Masking is recorded as none (open label)
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 49 other studies in this databaseCounted from the lead sponsor named in the record (NRG Oncology)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: other.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding0/20
Open-label
Control arm15/15
Active-comparator control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 832 sites
Data monitoring committee7/7
A data monitoring committee is in place
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,670 participants (target), run at 832 sites, across 4 countries.

How this score is built

Enrolment32/40
1,670 participants (target)
Site count25/25
832 sites
Country count7/15
4 countries
Planned duration10/10
Planned over about 244 months
Sponsor scale6/10
NRG Oncology has led 49 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

Breast conservation therapy for early stage breast cancer has been an important achievement of oncology practice in the last half century and breast radiotherapy (RT) has been essential in its development. Several seminal randomized clinical trials conducted in the 1980's era demonstrated that breast radiotherapy following lumpectomy yielded overall survival outcomes equivalent to mastectomy for treatment of early stage invasive breast cancer leading to the National Institute of Health (NIH) Consensus Conference statement in 1991 supporting breast conservation treatment.This established lumpectomy with RT as an alternative to mastectomy and subsequently the rate of breast conservation for eligible breast cancer patients rose steadily. Shortly thereafter, investigators recognized that the toxicity, patient burden, and geographic barriers associated with the protracted treatment course for breast RT was a potential barrier to breast conservation utilization. Numerous phase III clinical trials were conducted randomizing women post lumpectomy to RT vs. observation aimed at identifying which cases did not derive a significant RT benefit. No such subsets of breast cancer patients were consistently identified, thereby solidifying the standard that breast conservation required both lumpectomy and RT. Two meta-analyses by the Early Breast Cancer Trialists Collaborative Group (EBCTCG) in 2005 and 2011 further reinforced the value of breast RT post lumpectomy by examining the relationship of local recurrence and breast cancer mortality relative to the use of breast RT post lumpectomy. In each analysis, it found for axillary node negative breast cancer patients undergoing breast conservation a small but consistent increase in breast cancer mortality when breast radiotherapy was omitted. As a result, breast RT after lumpectomy has become an established paradigm for breast conservation for early stage breast cancer and is recommended by the NCCN 2018 guidelines (as it has for nearly two decades) that are commonly used today by clinicians and health systems alike. The landscape of early stage breast cancer has changed dramatically over the past three decades since the establishment of breast conservation. Widespread screening with mammography has led to the diagnosis of smaller and earlier stage disease. All breast cancers are now routinely characterized by their hormone sensitivity based on the presence of estrogen and progesterone receptors on tumor cells within the biopsy or surgical specimen and presence of HER2 (human epidermal growth factor receptor 2) which has provided an additional means of stratifying breast cancer into distinct prognostic groups. Small, node negative invasive breast cancer that is hormone sensitive (HS) and HER2-negative has a lower overall recurrence rate (local, regional, and distant) than breast cancers characterized by more adverse clinical pathologic features. However, other than in a smaller subset of women greater than 70 years old, clinical trials in this HS population still demonstrated unacceptable local recurrence risks long term after lumpectomy alone emphasizing that clinical and pathologic features are insufficient for consistently identifying when RT can safely be omitted.

Erkrankungen

Stage I Breast Cancer

Eignung

Eignung
Geschlecht	Alle
Alter	50 Years – 70 Years
Gesunde Freiwillige	Nein

Eignung im Wortlaut des Registers

Inclusion Criteria: * • The patient or a legally authorized representative must provide study-specific informed consent prior to pre-entry/Step 1 and, for patients treated in the U.S., authorization permitting release of personal health information. * The patient must have an ECOG performance status of 0 or 1. * The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for LCIS are eligible without additional resection.) * The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination. * Patient must have undergone axillary staging (sentinel node biopsy and/or axillary node dissection). * The following staging criteria must be met postoperatively according to AJCC 8th edition criteria: * By pathologic evaluation, primary tumor must be pT1 (less than or equal to 2 cm). * By pathologic evaluation, ipsilateral nodes must be pN0. (Patients with pathologic staging of pN0(i+) or pN0(mol+) are NOT eligible.) * Oncotype DX Recurrence Score of less than or equal to 18 on diagnostic core biopsy or resected specimen. \*\* For patients with a T1a tumor (less than or equal to 0.5 cm in size) or patients at Canadian provinces or approved international sites where Oncotype DX Recurrence Score testing would not be covered, who do not already have an Oncotype DX Recurrence Score at pre-entry/Step 1, a specimen (unstained blocks or slides) must be sent to the Genomic Health centralized laboratory. Tumor size sample must be greater than or equal to 0.2 cm for analysis. \*\*\* The Oncotype RS can be run on the biopsy core or surgical specimen. The patient cannot have initiated endocrine therapy prior to tissue collection. * An Oncotype RS is required for eligibility, however, for a patient whose tumor has already had a MammaPrint test completed as part of usual care when being considered for enrollment and is in the binary "Low" category will meet this eligibility criteria and an Oncotype RS does not need to be performed. * The tumor must have been determined to be ER and/or PgR positive assessed by current ASCO/CAP Guideline Recommendations for hormone receptor testing. Patients with greater than or equal to 1% ER or PgR staining by IHC are considered positive. * The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines. * Patients may be premenopausal or postmenopausal at the time of pre-entry/Step 1. For study purposes, postmenopausal is defined as: * Age 56 or older with no spontaneous menses for at least 12 months prior to pre-entry/Step 1; or a documented hysterectomy; or * Age 55 or younger with no spontaneous menses for at least 12 months prior to pre-entry/Step 1 (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or Documented bilateral oophorectomy. * The interval between the last surgery for breast cancer (including re-excision of margins) and pre-entry/Step 1 must be no more than 70 days. * The patient must have recovered from surgery with the incision completely healed and no signs of infection. * Bilateral mammogram or MRI within 6 months prior to pre-entry/Step 1. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients must be intending to take endocrine therapy for a minimum 5 years duration (tamoxifen or aromatase inhibitor). The specific regimen of endocrine therapy is at the treating physician's discretion. Exclusion Criteria: * • Definitive clinical or radiologic evidence of metastatic disease. * pT1 mi and pT2 - pT4 tumors including inflammatory breast cancer. * Pathologic staging of pN0(i+) or pN0(mol+), pN1, pN2, or pN3 disease. * Patient had a mastectomy. * Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor. * Suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign. * Non-epithelial breast malignancies such as sarcoma or lymphoma. * Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters. (Patients with multifocal carcinoma are eligible.) * Paget's disease of the nipple. * Any history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated or not treated. (Patients with synchronous or previous ipsilateral LCIS are eligible.) * Synchronous or previous contralateral invasive breast cancer or DCIS. (Patients with synchronous and/or previous contralateral LCIS are eligible.) * Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re- excision, the patient is eligible.) * Treatment plan that includes regional nodal irradiation. * Any treatment with radiation therapy, chemotherapy, or biotherapy, administered for the currently diagnosed breast cancer prior to pre-entry/Step 1. * History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to pre-entry/Step 1. * Current therapy with any endocrine therapy such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention. \*\* Patients are eligible for BR007 if they receive a short course of preoperative endocrine therapy of less than 6 weeks duration (prior to randomization/Step 2) for this diagnosis after the core biopsy (and can continue postoperatively if: * the Oncotype DX Recurrence Score is assessed on the biopsy core and is less than or equal to 18, AND * the patient had not initiated endocrine therapy prior to core biopsy tissue collection. \*\*\* This does not apply to adjuvant endocrine therapy recommended for this diagnosis which may start any time after surgery including prior to registration (Pre-entry/Step 1). * Patients intending to continue on oral, transdermal, or subdermal estrogen replacement (including all estrogen only and estrogen-progesterone formulas) are not eligible. Patients that discontinue oral, transdermal, or subdermal estrogen replacement prior to registration are eligible. * Prior breast or thoracic RT for any condition. * Active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma. * Pregnancy or lactation at the time of pre-entry/Step 1 or intention to become pregnant during treatment. (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to pre-entry/Step 1.) * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study therapy or that may affect the interpretation of the results or render the patient at high risk from treatment complications. * Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results. * Use of any investigational product within 30 days prior to pre-entry/Step 1.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
Studientyp	Interventionell
Phase	Phase 3
Zuteilung	Randomisiert
Interventionsmodell	PARALLEL
Primäres Ziel	TREATMENT
Verblindung	NONE (0)
Teilnahme	1.670 Teilnehmende gesucht

Sponsor und Mitwirkende

NRG Oncology Sponsor
National Cancer Institute (NCI) Mitwirkende

Studienarme und Interventionen

Arm 1: Breast Radiation Therapy + Endocrine TherapyACTIVE_COMPARATOR
Radiation therapy to the breast and hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily
Arm 2: No Breast Radiation Therapy + Endocrine TherapyACTIVE_COMPARATOR
No radiation therapy, only hormonal drug for at least 5 years. Tamoxifen 20 mg daily Anastrozole 1 mg daily Letrozole 2.5 mg daily Exemestane 25 mg daily

Interventionen

Arzneimittel Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
Sonstige Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins). Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator.

Endpunkte

Primärer Endpunkt
Time to invasive or noninvasive IBTR.
Time from randomization to any invasive or noninvasive IBTR or last follow-up (expressed as % IBTR-free)
Zeitrahmen 5 years
Sekundärer Endpunkt
Percent of women with an intact index breast at report of the primary endpoint inclusive of salvage second breast conservation procedures.
Time from randomization to any breast procedure after the initial surgery or last follow-up (expressed as % with intact index breast)
Zeitrahmen Through study completion, an average of 15 years.
Sekundärer Endpunkt
Time from randomization to the first occurrence of invasive ipsilateral breast tumor recurrence.
Time from randomization to any invasive IBTR or last follow-up (expressed as percentage of invasive IBTR-free
Zeitrahmen 5 years
Sekundärer Endpunkt
Time from randomization to diagnosis of a local, regional or distant recurrence as a first cancer event.
Time from randomization to any breast cancer recurrence at a local, regional or distant site or last follow-up (expressed as percentage of recurrence-free)
Zeitrahmen 5 years
Sekundärer Endpunkt
Time from randomization to the first distant cancer event (either a recurrence or a secondary primary cancer).
Time from randomization to any cancer occurring at a distant site or last follow-up (expressed as percentage of distant disease-free)
Zeitrahmen 5 years
Sekundärer Endpunkt
Time from randomization to any death.
Time from randomization to any death or last follow-up (expressed as percent surviving)
Zeitrahmen 5 years

Daten

Daten
Startdatum	23. Juni 2021 (tatsächlich)
Primärer Abschluss	8. April 2031 (geschätzt)
Abschluss	1. Juli 2041 (geschätzt)
Erstveröffentlichung	21. April 2021 (tatsächlich)
Zuletzt aktualisiert	23. April 2026
Ergebnisse veröffentlicht	Im Registereintrag nicht angegeben
Status zuletzt bestätigt	April 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

726 Studienzentren rekrutieren

Canada

Canada
Einrichtung	Stadt	Bundesland oder Region	Status
Kingston Health Sciences Centre	Kingston	Ontario	Rekrutiert
CHUM - Centre Hospitalier de l'Universite de Montreal	Montreal	Quebec	Rekrutiert
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)	Québec	Quebec	Rekrutiert
Allan Blair Cancer Centre	Regina	Saskatchewan	Rekrutiert
Atlantic Health Sciences Corporation-Saint John Regional Hospital	Saint John	New Brunswick	Rekrutiert
Saskatoon Cancer Centre	Saskatoon	Saskatchewan	Rekrutiert
Odette Cancer Centre- Sunnybrook Health Sciences Centre	Toronto	Ontario	Rekrutiert

Hong Kong

Hong Kong
Einrichtung	Stadt	Bundesland oder Region	Status
Pamela Youde Nethersole Eastern Hospital	Chai Wan		Ausgesetzt

Japan

Japan
Einrichtung	Stadt	Bundesland oder Region	Status
Hyogo Cancer Center	Akashi	Hyōgo	Rekrutiert
Gunma University Hospital	Gunma	Maebashi	Rekrutiert
Hiroshima University Hospital	Hiroshima		Rekrutiert
The Cancer Institute Hospital Of JFCR	Koto-ku	Tokyo	Rekrutiert
Kyoto University Hospital	Kyoto		Rekrutiert
Shikoku Cancer Center	Matsuyama		Rekrutiert
Nagoya University Hospital	Nagoya		Rekrutiert
Kindai University	Osaka		Rekrutiert
Saitama Medical University International Medical Center	Saitama		Rekrutiert
Hokkaido University Hospital	Sapporo	Hokkaido	Rekrutiert
National Cancer Center Hospital	Tokyo		Rekrutiert
Ehime University Hospital	Tōon	Ehime	Rekrutiert

United States

United States
Einrichtung	Stadt	Bundesland oder Region	Status
Hendrick Medical Center	Abilene	Texas	Aktiv, rekrutiert nicht
Summa Health System - Akron Campus	Akron	Ohio	Rekrutiert
Cleveland Clinic Akron General	Akron	Ohio	Rekrutiert
Atrium Health Stanly/LCI-Albemarle	Albemarle	North Carolina	Rekrutiert
Mayo Clinic Health System in Albert Lea	Albert Lea	Minnesota	Rekrutiert
University of New Mexico Cancer Center	Albuquerque	New Mexico	Rekrutiert
Saint Luke's Cancer Center - Allentown	Allentown	Pennsylvania	Ausgesetzt
Northside Hospital-Alpharetta	Alpharetta	Georgia	Rekrutiert
AdventHealth Altamonte	Altamonte Springs	Florida	Rekrutiert
Alton Memorial Hospital	Alton	Illinois	Aktiv, rekrutiert nicht
American Fork Hospital / Huntsman Intermountain Cancer Center	American Fork	Utah	Rekrutiert
McFarland Clinic - Ames	Ames	Iowa	Rekrutiert
Mary Greeley Medical Center	Ames	Iowa	Rekrutiert
Kaiser Permanente-Anaheim	Anaheim	California	Rekrutiert
UI Health Care Mission Cancer and Blood - Ankeny Clinic	Ankeny	Iowa	Rekrutiert
University of Michigan Rogel Cancer Center	Ann Arbor	Michigan	Rekrutiert
Trinity Health Saint Joseph Mercy Hospital Ann Arbor	Ann Arbor	Michigan	Rekrutiert
Langlade Hospital and Cancer Center	Antigo	Wisconsin	Rekrutiert
Kaiser Permanente-Deer Valley Medical Center	Antioch	California	Rekrutiert
ThedaCare Regional Cancer Center	Appleton	Wisconsin	Aktiv, rekrutiert nicht
Mission Hope Medical Oncology - Arroyo Grande	Arroyo Grande	California	Rekrutiert
PCR Oncology	Arroyo Grande	California	Rekrutiert
Mission Hospital	Asheville	North Carolina	Rekrutiert
Hope Women's Cancer Centers-Asheville	Asheville	North Carolina	Rekrutiert
Mount Sinai Queens	Astoria	New York	Rekrutiert
Emory University Hospital/Winship Cancer Institute	Atlanta	Georgia	Rekrutiert
Emory Saint Joseph's Hospital	Atlanta	Georgia	Rekrutiert
Grady Health System	Atlanta	Georgia	Rekrutiert
Emory University Hospital Midtown	Atlanta	Georgia	Rekrutiert
Piedmont Hospital	Atlanta	Georgia	Rekrutiert

782 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.

Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.

https://xmedica.io/trials/ctgov/NCT04852887